HRP20192133T1 - Kemijski spoj koristan kao posrednik za pripremu inhibitora katekol-o-metiltransferaze - Google Patents
Kemijski spoj koristan kao posrednik za pripremu inhibitora katekol-o-metiltransferaze Download PDFInfo
- Publication number
- HRP20192133T1 HRP20192133T1 HRP20192133TT HRP20192133T HRP20192133T1 HR P20192133 T1 HRP20192133 T1 HR P20192133T1 HR P20192133T T HRP20192133T T HR P20192133TT HR P20192133 T HRP20192133 T HR P20192133T HR P20192133 T1 HRP20192133 T1 HR P20192133T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- formula
- crystallized form
- micronized microparticles
- edc
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 6
- 229940099362 Catechol O methyltransferase inhibitor Drugs 0.000 title 1
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 title 1
- 239000011859 microparticle Substances 0.000 claims 5
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 102000003823 Aromatic-L-amino-acid decarboxylases Human genes 0.000 claims 1
- 108090000121 Aromatic-L-amino-acid decarboxylases Proteins 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 229940124639 Selective inhibitor Drugs 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 230000001079 digestive effect Effects 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960004502 levodopa Drugs 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (6)
1. Farmaceutski pripravak u jediničnom obliku doziranja za oralnu primjenu, koji sadrži spoj formule (II)
u kristaliziranom obliku mikroniziranih mikročestica u farmaceutski prihvatljivom nosaču, naznačen time što D10 (EDC) nije manji od 4 µm, D50 (EDC) je 10-45 µm, a D95 (EDC) nije veći od 70 µm.
2. Farmaceutski pripravak prema bilo kojem od prethodnih zahtjeva, u obliku tablete ili kapsule.
3. Farmaceutski pripravak kako se navodi u bilo kojem od prethodnih zahtjeva, naznačen time što se kristalizirani oblik mikroniziranih mikročestica spoja formule (II) dobiva mikronizacijom kroz spiralne mlaznice.
4. Kristalizirani oblik mikroniziranih mikročestica spoja formule (II) prema zahtjevu 1 ili zahtjevu 3, za uporabu oralnom primjenom u liječenju poremećaja središnjeg i perifernog živčanog sustava, poput Parkinsonove bolesti, poremećaja raspoloženja, sindroma nemirnih nogu, probavnih smetnji, stanja stvaranja edema i hipertenzije.
5. Kristalizirani oblik mikroniziranih mikročestica spoja formule za uporabu prema zahtjevu 4, naznačen time što se uporaba odnosi na liječenje Parkinsonove bolesti.
6. Kristalizirani oblik mikroniziranih mikročestica spoja formule za uporabu prema zahtjevu 4 ili 5, naznačen time što uporaba nadalje uključuje davanje pacijentu koji boluje od Parkinsonove bolesti učinkovite količine levodope i periferno selektivnog inhibitora dekarboksilaze aromatske aminokiseline.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161570141P | 2011-12-13 | 2011-12-13 | |
GBGB1121413.7A GB201121413D0 (en) | 2011-12-13 | 2011-12-13 | Chemical compounds and processes |
US201261593625P | 2012-02-01 | 2012-02-01 | |
GBGB1201758.8A GB201201758D0 (en) | 2012-02-01 | 2012-02-01 | Chemical compounds and processes |
US201261718589P | 2012-10-25 | 2012-10-25 | |
PCT/PT2012/000048 WO2013089573A1 (en) | 2011-12-13 | 2012-12-12 | Chemical compound useful as intermediate for preparing a catechol-o-methyltransferase inhibitor |
EP12806720.4A EP2791134B1 (en) | 2011-12-13 | 2012-12-12 | Chemical compound useful as intermediate for preparing a catechol-o-methyltransferase inhibitor |
Publications (2)
Publication Number | Publication Date |
---|---|
HRP20192133T1 true HRP20192133T1 (hr) | 2020-02-21 |
HRP20192133T8 HRP20192133T8 (hr) | 2021-02-19 |
Family
ID=48612903
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20192133TT HRP20192133T8 (hr) | 2011-12-13 | 2019-11-27 | Kemijski spoj koristan kao posrednik za pripremu inhibitora katekol-o-metiltransferaze |
Country Status (15)
Country | Link |
---|---|
US (2) | US9126988B2 (hr) |
EP (2) | EP2791134B1 (hr) |
JP (3) | JP6456143B2 (hr) |
BR (1) | BR112014014341A2 (hr) |
CA (2) | CA3088684C (hr) |
CY (1) | CY1122580T1 (hr) |
DK (1) | DK2791134T3 (hr) |
ES (2) | ES2758659T3 (hr) |
HR (1) | HRP20192133T8 (hr) |
HU (1) | HUE047856T2 (hr) |
PL (1) | PL2791134T3 (hr) |
PT (2) | PT3604299T (hr) |
RS (1) | RS59666B1 (hr) |
SI (1) | SI2791134T1 (hr) |
WO (1) | WO2013089573A1 (hr) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101370280B1 (ko) | 2005-07-26 | 2014-03-06 | 바이알 - 포르텔라 앤드 씨에이 에스에이 | Comt 억제제로서의 니트로카테콜 유도체 |
EP1845097A1 (en) | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
AU2007346018A1 (en) | 2007-01-31 | 2008-08-07 | Bial - Portela & Ca, S.A. | Dosage regimen for COMT inhibitors |
AR070907A1 (es) | 2008-03-17 | 2010-05-12 | Bial Portela & Ca Sa | Formas cristalinas de derivado de nitrocatecol |
CN102448444B (zh) | 2009-04-01 | 2016-05-25 | 巴尔-波特拉及康邦亚股份有限公司 | 包括硝基儿茶酚衍生物的药物制剂及其制备方法 |
US20140045900A1 (en) | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
DK2791134T3 (da) * | 2011-12-13 | 2019-12-09 | BIAL PORTELA & Cª S A | Kemisk forbindelse, der er anvendelig som mellemprodukt til fremstilling af en catechol-o-methyltransferasehæmmer |
RU2017120184A (ru) | 2014-11-28 | 2018-12-28 | БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. | Лекарства для замедления течения болезни паркинсона |
GB2563858A (en) * | 2017-06-27 | 2019-01-02 | Azad Pharmaceutical Ingredients Ag | New route of synthesis for opicapone |
US20210087183A1 (en) * | 2017-12-18 | 2021-03-25 | Unichem Laboratories Ltd | Process for the preparation of opicapone and intermediates thereof |
CA3112994A1 (en) | 2018-10-05 | 2020-04-09 | Neurocrine Biosciences, Inc. | Methods for the administration of comt inhibitors |
WO2020072886A1 (en) | 2018-10-05 | 2020-04-09 | Neurocrine Biosciences, Inc. | Methods for the administration of comt inhibitors |
CN109529881A (zh) * | 2018-11-12 | 2019-03-29 | 刘晓菊 | 一种治疗帕金森药物用中间体5-硝基香草酸的制备方法 |
BR112022017401A2 (pt) | 2020-03-13 | 2022-10-18 | Bial Portela & Ca Sa | Opicapona micronizada |
GB202011709D0 (en) | 2020-07-28 | 2020-09-09 | Bial Portela & Ca Sa | Solid dispersion of opicapone |
GB202016425D0 (en) | 2020-10-16 | 2020-12-02 | Bial Portela & Ca Sa | Treatment regimens for parkinson's disease |
CN112375014A (zh) * | 2020-12-17 | 2021-02-19 | 重庆柳江医药科技有限公司 | 一种奥匹卡朋工艺杂质及制备方法和用途 |
EP4262798A1 (en) | 2020-12-17 | 2023-10-25 | Bial-Portela & CA, S.A. | Treatment regimens for early idiopathic parkinson's disease |
WO2022180649A1 (en) * | 2021-02-26 | 2022-09-01 | Msn Laboratories Private Limited, R&D Center | Novel process for the preparation of 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine-1-oxide |
CN113292489B (zh) * | 2021-06-16 | 2022-08-30 | 泓博智源(开原)药业有限公司 | 二氯代二烷基烟腈的制备方法 |
GB202204798D0 (en) | 2022-04-01 | 2022-05-18 | Bial Portela & Ca Sa | Prodrugs of opicapone |
GB202212082D0 (en) | 2022-08-18 | 2022-10-05 | Bial Portela & Ca Sa | Treatment regimens for parkinson's disease |
GB202219669D0 (en) | 2022-12-23 | 2023-02-08 | Bial Portela & Ca Sa | Processes and intermediates for synthesising opicapone |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1532178A (en) | 1921-07-25 | 1925-04-07 | Louis A Godbold | Lubricator |
FR1260080A (fr) | 1960-03-22 | 1961-05-05 | Materiel De Forage Soc De Fab | Trépan à molettes étanche |
IL31990A (en) | 1968-04-26 | 1974-05-16 | Chinoin Gyogyszer Es Vegyeszet | Pyridyl 1,2,4-oxadiazole derivatives,process for the preparation thereof and pharmaceutical compositions containing same |
US4022901A (en) | 1975-03-05 | 1977-05-10 | E. R. Squibb & Sons, Inc. | 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles |
US4264573A (en) | 1979-05-21 | 1981-04-28 | Rowell Laboratories, Inc. | Pharmaceutical formulation for slow release via controlled surface erosion |
US4386668A (en) | 1980-09-19 | 1983-06-07 | Hughes Tool Company | Sealed lubricated and air cooled rock bit bearing |
US5236952A (en) | 1986-03-11 | 1993-08-17 | Hoffmann-La Roche Inc. | Catechol derivatives |
DK175069B1 (da) | 1986-03-11 | 2004-05-24 | Hoffmann La Roche | Pyrocatecholderivater |
YU213587A (en) | 1986-11-28 | 1989-06-30 | Orion Yhtymae Oy | Process for obtaining new pharmacologic active cateholic derivatives |
DE3840954A1 (de) | 1988-12-05 | 1990-06-07 | Shell Int Research | Herstellung von 2-chlornicotinsaeureestern |
US5206372A (en) | 1990-06-05 | 1993-04-27 | Shell Research Limited | Preparation of 2-chloropyridine derivatives |
DE69013689T2 (de) | 1990-11-29 | 1995-03-02 | Wei Ming Pharmaceutical Mfg Co | Hilfsträger für direkte Verpressung. |
JPH07502529A (ja) | 1991-12-31 | 1995-03-16 | 藤沢薬品工業株式会社 | アセチルコリンエステラーゼ阻害およびムスカリン様のアゴニスト活性を有するオキサジアゾール誘導体 |
FR2730322B1 (fr) | 1995-02-02 | 1997-04-30 | Imago | Monture de lunettes metallique |
DE19628617A1 (de) | 1996-07-16 | 1998-01-22 | Basf Ag | Direkttablettierhilfsmittel |
US6206110B1 (en) | 1996-09-09 | 2001-03-27 | Smith International, Inc. | Protected lubricant reservoir with pressure control for sealed bearing earth boring drill bit |
AU762245B2 (en) | 1998-09-18 | 2003-06-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
GB2344819A (en) | 1998-12-18 | 2000-06-21 | Portela & Ca Sa | 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones |
FI109453B (fi) | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
US6660753B2 (en) | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
CZ2002599A3 (cs) | 1999-08-19 | 2002-06-12 | Nps Pharmaceuticals Inc. | Heteropolycyklické sloučeniny a jejich pouľití jako antagonistů metabotropního receptoru glutamátu |
FI20000635A0 (fi) | 2000-03-17 | 2000-03-17 | Orion Yhtymae Oyj | COMT-inhibiittoreiden käyttö analgeettina |
SE0001438D0 (sv) | 2000-04-18 | 2000-04-18 | Axon Chemicals Bv | New chemical compounds and their use in therapy |
DE10029201A1 (de) | 2000-06-19 | 2001-12-20 | Basf Ag | Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung |
GB2363792A (en) | 2000-06-21 | 2002-01-09 | Portela & Ca Sa | Nitrocatechols |
CN1166626C (zh) | 2000-08-30 | 2004-09-15 | 李凌松 | 三或四取代苯基化合物、其制备方法及应用 |
JP2004532611A (ja) | 2000-11-28 | 2004-10-28 | ザイモジェネティクス,インコーポレイティド | サイトカイン受容体zcytor19 |
US20040097555A1 (en) | 2000-12-26 | 2004-05-20 | Shinegori Ohkawa | Concomitant drugs |
WO2002051442A1 (fr) | 2000-12-26 | 2002-07-04 | Takeda Chemical Industries, Ltd. | Co-prescriptions |
ATE375340T1 (de) | 2001-02-21 | 2007-10-15 | Nps Pharma Inc | Heteropolycyclische verbindungen und deren verwendung als metabotrope glutamatrezeptorantagonisten |
WO2002096867A2 (en) | 2001-05-30 | 2002-12-05 | Lg Biomedical Institute | Inhibitors of protein kinase for the treatment of disease |
KR20040004705A (ko) | 2001-06-08 | 2004-01-13 | 시토비아 인크. | 카스파제의 활성제 및 아폽토시스의 유도제로서의 치환된3-아릴-5-아릴-[1,2,4]-옥사디아졸과 유사체 및 이의 용도 |
ES2280602T3 (es) | 2001-07-26 | 2007-09-16 | Merck Patent Gmbh | Uso de 2-(5-(4-fluorofenil)-3-piridilmetilaminometil)-cromano y sus sales fisiologicamente aceptables. |
JP4379853B2 (ja) | 2001-10-05 | 2009-12-09 | 惠民製藥股▲分▼有限公司 | 直接錠剤化用調合物および補助剤の調合方法 |
WO2004058253A1 (en) | 2002-12-18 | 2004-07-15 | Cytovia, Inc. | 3,5-disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof |
WO2005006945A2 (en) | 2003-07-03 | 2005-01-27 | The Salk Institute For Biological Studies | Methods for treating neural disorders and compounds useful therefor |
JP4889489B2 (ja) | 2003-08-06 | 2012-03-07 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼのインヒビターとして有用なアミノトリアゾール化合物 |
DE10338174A1 (de) | 2003-08-20 | 2005-03-24 | Lts Lohmann Therapie-Systeme Ag | Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit |
US7300406B2 (en) | 2003-09-30 | 2007-11-27 | Carter Vandette B | Medical examination apparatus |
GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
DE602005020611D1 (de) | 2004-04-28 | 2010-05-27 | Vertex Pharma | Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen |
GB0510143D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
WO2006051154A1 (en) | 2004-11-10 | 2006-05-18 | Orion Corporation | Treatment of restless legs syndrome |
WO2006061697A1 (en) | 2004-12-06 | 2006-06-15 | Themis Laboratories Private Limited | Sulfonylurea compositions and a process for its preparation |
US20080051441A1 (en) | 2004-12-28 | 2008-02-28 | Astrazeneca Ab | Aryl Sulphonamide Modulators |
JP2008525524A (ja) | 2004-12-28 | 2008-07-17 | アストラゼネカ・アクチエボラーグ | アリールスルホンアミドモジュレーター |
RU2007139255A (ru) | 2005-04-26 | 2009-06-10 | Ньюросерч А/С (DK) | Новые оксадиазольные производные и их медицинское применение |
US20060257473A1 (en) | 2005-05-11 | 2006-11-16 | Porranee Puranajoti | Extended release tablet |
GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
CA2610655A1 (en) | 2005-06-03 | 2006-12-14 | Abbott Laboratories | Cyclobutyl amine derivatives |
JP2007024970A (ja) | 2005-07-12 | 2007-02-01 | Miyakawa:Kk | 液晶表示装置の開口効率を上昇させるための樹脂レンズ製造法及びその製造装置 |
US20090000437A1 (en) | 2005-07-14 | 2009-01-01 | Provo Craft And Novelty, Inc. | Methods for Cutting |
KR101370280B1 (ko) * | 2005-07-26 | 2014-03-06 | 바이알 - 포르텔라 앤드 씨에이 에스에이 | Comt 억제제로서의 니트로카테콜 유도체 |
FR2889525A1 (fr) | 2005-08-04 | 2007-02-09 | Palumed Sa | Nouveaux derives de polyquinoleines et leur utilisation therapeutique. |
US20070048384A1 (en) | 2005-08-26 | 2007-03-01 | Joerg Rosenberg | Pharmaceutical compositions |
US20090111778A1 (en) | 2005-11-18 | 2009-04-30 | Richard Apodaca | 2-Keto-Oxazoles as Modulators of Fatty Acid Amide Hydrolase |
JP4738419B2 (ja) | 2005-11-30 | 2011-08-03 | 富士フイルムRiファーマ株式会社 | アミロイドの凝集及び/又は沈着に起因する疾患の診断薬及び治療薬 |
GB0606774D0 (en) | 2006-04-03 | 2006-05-10 | Novartis Ag | Organic compounds |
EP1845097A1 (en) | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
PE20080906A1 (es) | 2006-08-17 | 2008-07-05 | Kemia Inc | Derivados heteroarilo como inhibidores de citocina |
US20080167286A1 (en) | 2006-12-12 | 2008-07-10 | Abbott Laboratories | Pharmaceutical compositions and their methods of use |
US8486979B2 (en) | 2006-12-12 | 2013-07-16 | Abbvie Inc. | 1,2,4 oxadiazole compounds and methods of use thereof |
AU2007346018A1 (en) * | 2007-01-31 | 2008-08-07 | Bial - Portela & Ca, S.A. | Dosage regimen for COMT inhibitors |
CN104072489B (zh) | 2007-08-27 | 2017-07-07 | 达特神经科学(开曼)有限公司 | 治疗用异噁唑化合物 |
WO2009108077A2 (en) | 2008-02-28 | 2009-09-03 | Bial - Portela & Ca., S.A. | Pharmaceutical composition for poorly soluble drugs |
AR070907A1 (es) | 2008-03-17 | 2010-05-12 | Bial Portela & Ca Sa | Formas cristalinas de derivado de nitrocatecol |
JP6165412B2 (ja) | 2008-07-29 | 2017-07-19 | ノヴィファーマ,エス.アー. | ニトロカテコールの投与計画 |
CN102438595B (zh) | 2009-04-01 | 2016-04-27 | 巴尔-波特拉及康邦亚股份有限公司 | 包括硝基儿茶酚衍生物的药物制剂及其制备方法 |
CN102448444B (zh) | 2009-04-01 | 2016-05-25 | 巴尔-波特拉及康邦亚股份有限公司 | 包括硝基儿茶酚衍生物的药物制剂及其制备方法 |
AU2011222856B2 (en) | 2010-03-04 | 2015-10-15 | Orion Corporation | Use of levodopa, carbidopa and entacapone for treating Parkinson's disease |
US20140045900A1 (en) * | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
DK2791134T3 (da) * | 2011-12-13 | 2019-12-09 | BIAL PORTELA & Cª S A | Kemisk forbindelse, der er anvendelig som mellemprodukt til fremstilling af en catechol-o-methyltransferasehæmmer |
-
2012
- 2012-12-12 DK DK12806720T patent/DK2791134T3/da active
- 2012-12-12 SI SI201231703T patent/SI2791134T1/sl unknown
- 2012-12-12 CA CA3088684A patent/CA3088684C/en active Active
- 2012-12-12 ES ES12806720T patent/ES2758659T3/es active Active
- 2012-12-12 CA CA2858025A patent/CA2858025C/en active Active
- 2012-12-12 JP JP2014547135A patent/JP6456143B2/ja active Active
- 2012-12-12 WO PCT/PT2012/000048 patent/WO2013089573A1/en active Application Filing
- 2012-12-12 PT PT191947563T patent/PT3604299T/pt unknown
- 2012-12-12 BR BR112014014341A patent/BR112014014341A2/pt not_active Application Discontinuation
- 2012-12-12 US US14/365,265 patent/US9126988B2/en active Active
- 2012-12-12 PT PT128067204T patent/PT2791134T/pt unknown
- 2012-12-12 RS RS20191562A patent/RS59666B1/sr unknown
- 2012-12-12 HU HUE12806720A patent/HUE047856T2/hu unknown
- 2012-12-12 EP EP12806720.4A patent/EP2791134B1/en active Active
- 2012-12-12 ES ES19194756T patent/ES2960805T3/es active Active
- 2012-12-12 PL PL12806720T patent/PL2791134T3/pl unknown
- 2012-12-12 EP EP19194756.3A patent/EP3604299B1/en active Active
-
2015
- 2015-07-31 US US14/814,603 patent/US9630955B2/en active Active
-
2017
- 2017-10-27 JP JP2017207738A patent/JP6721558B2/ja active Active
-
2019
- 2019-11-27 JP JP2019214566A patent/JP2020059729A/ja not_active Withdrawn
- 2019-11-27 CY CY20191101241T patent/CY1122580T1/el unknown
- 2019-11-27 HR HRP20192133TT patent/HRP20192133T8/hr unknown
Also Published As
Publication number | Publication date |
---|---|
PL2791134T3 (pl) | 2020-03-31 |
HRP20192133T8 (hr) | 2021-02-19 |
US20160009700A1 (en) | 2016-01-14 |
RS59666B1 (sr) | 2020-01-31 |
US20140350057A1 (en) | 2014-11-27 |
ES2960805T3 (es) | 2024-03-06 |
JP2018052949A (ja) | 2018-04-05 |
DK2791134T3 (da) | 2019-12-09 |
JP2020059729A (ja) | 2020-04-16 |
EP2791134A1 (en) | 2014-10-22 |
CA3088684A1 (en) | 2013-06-20 |
PT3604299T (pt) | 2023-10-31 |
EP2791134B1 (en) | 2019-09-25 |
HUE047856T2 (hu) | 2020-05-28 |
US9630955B2 (en) | 2017-04-25 |
CA2858025A1 (en) | 2013-06-20 |
US9126988B2 (en) | 2015-09-08 |
CA3088684C (en) | 2021-10-26 |
JP2015500335A (ja) | 2015-01-05 |
ES2758659T3 (es) | 2020-05-06 |
JP6456143B2 (ja) | 2019-01-23 |
JP6721558B2 (ja) | 2020-07-15 |
EP3604299A1 (en) | 2020-02-05 |
WO2013089573A1 (en) | 2013-06-20 |
PT2791134T (pt) | 2019-12-18 |
CY1122580T1 (el) | 2021-01-27 |
SI2791134T1 (sl) | 2020-01-31 |
CA2858025C (en) | 2020-09-22 |
EP3604299B1 (en) | 2023-07-26 |
BR112014014341A2 (pt) | 2017-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20192133T1 (hr) | Kemijski spoj koristan kao posrednik za pripremu inhibitora katekol-o-metiltransferaze | |
NZ605887A (en) | Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain | |
WO2012116290A3 (en) | Neuroactive 17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same | |
WO2012035559A3 (en) | Sustained release pharmaceutical compositions comprising pregabalin | |
JP2012236834A5 (hr) | ||
JP2011173928A5 (hr) | ||
RU2010141331A (ru) | Новая доза и препаративная форма | |
RU2011138490A (ru) | Фармацевтические композиции с мгновенным высвобождением, содержащие оксикодон и налоксон | |
JP2010522240A5 (hr) | ||
MX2012000488A (es) | Terapia de combinacion para el tratamiento de la diabetes. | |
JP2018513171A5 (hr) | ||
US10239848B2 (en) | Cyclohexenyl compounds, compositions comprising them and uses thereof | |
MX2012009079A (es) | Formulaciones de rasagilina de liberación prolongada y usos de las mismas. | |
GEP20166483B (en) | Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament | |
EA200901146A1 (ru) | Твердые лекарственные формы, содержащие алискирен и его фармацевтически приемлемые соли | |
HRP20201736T1 (hr) | Postupak liječenja diskinezije | |
MX2011008627A (es) | Metodos de administracion de (4ar, 10ar)-1-n-propil-1,2,3,4,4a,5,1 0,10a-octahidro-benzo[g]quinolin-6,7-diol y compuestos relacionados a traves de la mucosa oral, la mucosa nasal o la piel y composiciones farmaceuticas de los mismos. | |
JP2016505050A5 (hr) | ||
JP2018533601A5 (hr) | ||
EA201101622A1 (ru) | Пептидная фармацевтическая композиция, средство на ее основе для лечения гастродуоденальных заболеваний, вызываемых helicobacter pylori, и способ его использования | |
WO2011121607A3 (en) | Rasagiline and its pharmaceutically acceptable salts | |
JP2013500943A5 (hr) | ||
HRP20170564T1 (hr) | Derivati aminociklobutana, metoda njihove priprave i njihova upotreba za lijekove | |
AU2013216632B2 (en) | Intravenous antiviral treatments | |
JP2017513866A5 (hr) |